Biological Agents and Therapeutic Plasma Exchange: Can They Coexist in the Future? (Q47800187)

5 February 2018

editorial

0 references

title

Biological Agents and Therapeutic Plasma Exchange: Can They Coexist in the Future? (English)

1 reference

5 February 2018

1 reference

1

1 reference

5 February 2018

publication date

1 December 2017

1 reference

5 February 2018

Therapeutic Apheresis and Dialysis

published in

1 reference

5 February 2018

volume

21

1 reference

5 February 2018

issue

6

1 reference

5 February 2018

page(s)

553-555

1 reference

5 February 2018

Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.

cites work

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

Cryoglobulinemia Vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

FSGS Recurrence in Adults after Renal Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

Recurrent focal segmental glomerulosclerosis after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

Rituximab for Recurrence of Primary Focal Segmental Glomerulosclerosis After Kidney Transplantation: Clinical Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

Desensitization with plasmapheresis and anti-Cd20 for ABO incompatible kidney transplantation from living donor: experience of a single center in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

Rituximab for immunologic renal disease: What the nephrologist needs to know

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

Combined use of rituximab and plasmapheresis pre-transplant increases post-transplant infections in renal transplant recipients with basiliximab induction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

Eculizumab in secondary atypical haemolytic uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/1744-9987.12639

21 January 2018

Identifiers

DOI

10.1111/1744-9987.12639

1 reference

5 February 2018

1 reference

5 February 2018